PT  - JOURNAL ARTICLE
AU  - McGeoch, Malcolm. W.
AU  - McGeoch, Julie E. M.
TI  - COVID-19 Propagation and Mortality in a Two-Part Population
AID  - 10.1101/2020.05.17.20104356
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.17.20104356
4099  - http://medrxiv.org/content/early/2020/05/20/2020.05.17.20104356.short
4100  - http://medrxiv.org/content/early/2020/05/20/2020.05.17.20104356.full
AB  - There has recently emerged a striking consistency to the mortality from SARS-CoV-2, [1,2,3] as a fraction of population, across many nations. We have constructed a model for the spread of the virus that reproduces this phenomenon via inclusion of two (or more) categories of susceptibility to the virus. In the simplest case, the population is given a smaller fraction of 10-20% with higher susceptibility and the balance of 80-90% with lower susceptibility. Susceptibility is taken to include the level of immunity to the virus combined with the societal circumstances of certain smaller groups within a population. This is programmed numerically by considering a realistic random rate of contacts, together with an assumed constant viral genome. The remaining major variable is the societal response of nations to the outbreak, with earlier or later application of various degrees of lockdown, tracing and sanitation. China, South Korea and other nations, including Germany, have stopped or greatly slowed the spread of the disease before it could run its course through a whole population. Using this model the extent of progress toward herd immunity is discussed, with an in-principle estimate of the remaining toll to be experienced.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNAAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available